180 related articles for article (PubMed ID: 31187523)
1. Primary central nervous system lymphoma: A curable disease.
Batchelor TT
Hematol Oncol; 2019 Jun; 37 Suppl 1():15-18. PubMed ID: 31187523
[TBL] [Abstract][Full Text] [Related]
2. Primary central nervous system lymphoma.
Ferreri AJM; Calimeri T; Cwynarski K; Dietrich J; Grommes C; Hoang-Xuan K; Hu LS; Illerhaus G; Nayak L; Ponzoni M; Batchelor TT
Nat Rev Dis Primers; 2023 Jun; 9(1):29. PubMed ID: 37322012
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma.
Akingbemi W; Kurtz G; Yegya-Raman N; Plastaras JP; Schuster SJ; Chong EA
Leuk Lymphoma; 2024 Jun; 65(6):860-863. PubMed ID: 38451075
[No Abstract] [Full Text] [Related]
4. NCCN CNS tumor guidelines update for 2023.
Nabors B; Portnow J; Hattangadi-Gluth J; Horbinski C
Neuro Oncol; 2023 Dec; 25(12):2114-2116. PubMed ID: 37706665
[No Abstract] [Full Text] [Related]
5. Recent advances in the management of primary central nervous system lymphoma.
Choi YS
Blood Res; 2020 Jul; 55(S1):S58-S62. PubMed ID: 32719178
[TBL] [Abstract][Full Text] [Related]
6. Central Nervous System Lymphoma.
Chukwueke UN; Nayak L
Hematol Oncol Clin North Am; 2019 Aug; 33(4):597-611. PubMed ID: 31229157
[TBL] [Abstract][Full Text] [Related]
7. Primary central nervous system lymphoma: Novel precision therapies.
Mondello P; Mian M; Bertoni F
Crit Rev Oncol Hematol; 2019 Sep; 141():139-145. PubMed ID: 31295667
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiling of primary central nervous system lymphomas - predictive and prognostic value?
Ho KG; Grommes C
Curr Opin Neurol; 2019 Dec; 32(6):886-894. PubMed ID: 31592789
[TBL] [Abstract][Full Text] [Related]
9. Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma.
Holdhoff M; Mrugala MM; Grommes C; Kaley TJ; Swinnen LJ; Perez-Heydrich C; Nayak L
J Natl Compr Canc Netw; 2020 Nov; 18(11):1571-1578. PubMed ID: 33152700
[TBL] [Abstract][Full Text] [Related]
10. Primary Central Nervous System Lymphomas: A Diagnostic Overview of Key Histomorphologic, Immunophenotypic, and Genetic Features.
Lauw MIS; Lucas CG; Ohgami RS; Wen KW
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33322508
[TBL] [Abstract][Full Text] [Related]
11. Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients.
Sarid N; Bokstein F; Blumenthal DT; Weiss-Meilik A; Gibstein L; Avivi I; Perry C; Ram R
J Neurooncol; 2021 Jan; 151(2):211-220. PubMed ID: 33099747
[TBL] [Abstract][Full Text] [Related]
12. Central Nervous System Lymphoma: Approach to Diagnosis and Treatment.
Correia CE; Schaff LR; Grommes C
Cancer J; 2020; 26(3):241-252. PubMed ID: 32496457
[TBL] [Abstract][Full Text] [Related]
13. Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies.
Holdhoff M; Wagner-Johnston N; Roschewski M
Onco Targets Ther; 2020; 13():8323-8335. PubMed ID: 32903865
[TBL] [Abstract][Full Text] [Related]
14. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma.
Tateishi K; Miyake Y; Kawazu M; Sasaki N; Nakamura T; Sasame J; Yoshii Y; Ueno T; Miyake A; Watanabe J; Matsushita Y; Shiba N; Udaka N; Ohki K; Fink AL; Tummala SS; Natsumeda M; Ikegaya N; Nishi M; Ohtake M; Miyazaki R; Suenaga J; Murata H; Aoki I; Miller JJ; Fujii Y; Ryo A; Yamanaka S; Mano H; Cahill DP; Wakimoto H; Chi AS; Batchelor TT; Nagane M; Ichimura K; Yamamoto T
Cancer Res; 2020 Dec; 80(23):5330-5343. PubMed ID: 33067267
[TBL] [Abstract][Full Text] [Related]
15. Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.
Chihara D; Dunleavy K
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):73-79. PubMed ID: 33288483
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.
Dietrich J; Versmee L; Drappatz J; Eichler AF; Nayak L; Norden A; Wong E; Pisapia MR; Jones SS; Gordon AB; Chabner BA; Hochberg F; Batchelor TT
Oncologist; 2020 Sep; 25(9):747-e1273. PubMed ID: 32520407
[TBL] [Abstract][Full Text] [Related]
17. Is it time to revisit R-CHOP for primary CNS lymphoma?
Nayak L; Batchelor TT
Blood; 2019 Jul; 134(3):221-222. PubMed ID: 31320363
[No Abstract] [Full Text] [Related]
18. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment.
Zhang Y; Zhou DB
Chin Med J (Engl); 2020 Jun; 133(12):1462-1469. PubMed ID: 32452898
[TBL] [Abstract][Full Text] [Related]
19. On point in primary CNS lymphoma.
Tsang M; Cleveland J; Rubenstein JL
Hematol Oncol; 2020 Dec; 38(5):640-647. PubMed ID: 32510610
[TBL] [Abstract][Full Text] [Related]
20. Primary dural lymphomas: Clinical presentation, management, and outcome.
Karschnia P; Batchelor TT; Jordan JT; Shaw B; Winter SF; Barbiero FJ; Kaulen LD; Thon N; Tonn JC; Huttner AJ; Fulbright RK; Loeffler J; Dietrich J; Baehring JM
Cancer; 2020 Jun; 126(12):2811-2820. PubMed ID: 32176324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
